Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Cooper

Showing results (351-360 of 363) with videos related to

Pageof 37
Sort By:
Global Change Biology|March 19, 2013
Methane indicator values for peatlands: a comparison of species and functional groupsAlan Gray, Peter E Levy, Mark D A Cooper, et al.
The Journal of Infectious Diseases|August 11, 1998
Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient dataJ P Ioannidis, A C Collier, D A Cooper, et al.
Human Vaccines|October 3, 2006
Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjectsS Emery, C Workman, R L Puls, et al.
The New England Journal of Medicine|October 16, 2009
Interleukin-2 therapy in patients with HIV infection, , D Abrams, et al.
Biorxiv : the Preprint Server for Biology|June 10, 2024
Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S <i>ESR1</i> Mutant Breast Cancer CellsK S Young, G R Hancock, E Fink, et al.
The Journal of Infectious Diseases|June 1, 1996
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative GroupR T Schooley, C Ramirez-Ronda, J M Lange, et al.
Research Square|July 9, 2024
Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S <i>ESR1</i> Mutant Breast Cancer CellsK S Young, G R Hancock, E Fink, et al.
HIV Medicine|February 20, 2007
Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational DatabaseJ Zhou, N I Paton, R Ditangco, et al.
Breast Cancer Research : BCR|January 17, 2025
Targeting unique ligand binding domain structural features downregulates DKK1 in Y537S ESR1 mutant breast cancer cellsK S Young, G R Hancock, E C Fink, et al.
International Journal of Antimicrobial Agents|March 13, 1999
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trialA M Been-Tiktak, C A Boucher, F Brun-Vezinet, et al.
Pageof 37

Showing results (351-360 of 363) with videos related to

Sort By:
Pageof 37
Global Change Biology|March 19, 2013
Methane indicator values for peatlands: a comparison of species and functional groupsAlan Gray, Peter E Levy, Mark D A Cooper, et al.
The Journal of Infectious Diseases|August 11, 1998
Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient dataJ P Ioannidis, A C Collier, D A Cooper, et al.
Human Vaccines|October 3, 2006
Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjectsS Emery, C Workman, R L Puls, et al.
The New England Journal of Medicine|October 16, 2009
Interleukin-2 therapy in patients with HIV infection, , D Abrams, et al.
Biorxiv : the Preprint Server for Biology|June 10, 2024
Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S <i>ESR1</i> Mutant Breast Cancer CellsK S Young, G R Hancock, E Fink, et al.
The Journal of Infectious Diseases|June 1, 1996
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative GroupR T Schooley, C Ramirez-Ronda, J M Lange, et al.
Research Square|July 9, 2024
Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S <i>ESR1</i> Mutant Breast Cancer CellsK S Young, G R Hancock, E Fink, et al.
HIV Medicine|February 20, 2007
Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational DatabaseJ Zhou, N I Paton, R Ditangco, et al.
Breast Cancer Research : BCR|January 17, 2025
Targeting unique ligand binding domain structural features downregulates DKK1 in Y537S ESR1 mutant breast cancer cellsK S Young, G R Hancock, E C Fink, et al.
International Journal of Antimicrobial Agents|March 13, 1999
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trialA M Been-Tiktak, C A Boucher, F Brun-Vezinet, et al.
Pageof 37